StemoniX® microHeart® Selected as a Winner of CONNECT's 30th Annual Most Innovative New Product Awards

SAN DIEGO, Dec. 12, 2017 /PRNewswire/ -- CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences sectors, announced the winners of its 30th annual Most Innovative New Product Awards. The prestigious competition, which begins each year in the spring and culminates in the awards ceremony at the end of the year, is an annual signature event at CONNECT that recognizes and lauds stars of innovation and their latest groundbreaking products.

StemoniX® microHeart® was selected as CONNECT's Most Innovative New Product in the Life Science Diagnostics & Research Tools category. The CONNECT Award is the latest in a series of high-profile awards received by StemoniX. Recently, they were chosen as a Red Herring Global Top 100 company and the Minnesota Tekn? Award winner for most innovative startup.

With StemoniX's innovative microHeart technology, medicines can now be tested and perfected on physiologically accurate human heart cells before testing in humans. Pharmaceutical organizations are using microHeart products for their drug discovery and cardiac safety evaluations.

"We are fortunate to have a community that sees the value in our mission and puts a spotlight on game-changing new technologies," said Ping Yeh, co-founder and CEO of StemoniX. "We are proud to have microHeart chosen from among products designed by such extraordinary organizations as Biocept, Illumina, and TEGA Therapeutics. It is a true testament to the passion and efforts of our team, and we are grateful to our partners who have supported our innovative work. Our microHeart and microBrain platforms are changing how medicines are developed, so that they are safer for everyone."

ABOUT STEMONIX

StemoniX^® is transforming how medicine is discovered. Using skin or blood to create functioning microHearts^® and microBrains^®, StemoniX makes possible the testing of medications on humans without those medications ever entering their bodies. This method of drug testing will speed up the search for new therapies and enable the ability to test drug effectiveness on an individual person, so medicine works correctly the first time. Learn more at www.stemonix.com.

ABOUT CONNECT

CONNECT is a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences sectors. By creating an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources they need for success, CONNECT has assisted in the formation and development of more than 3,000 companies since 1985. Widely regarded as one of the world's most successful organizations linking entrepreneurs and C-suite executives with the resources they need for the commercialization of innovative products and services; our program has been modeled in more than 50 regions around the world.

Media Contact:
Ryan Gordon
StemoniX
612-440-7836
[email protected]

SOURCE StemoniX